Advertisement

PharmacoEconomics & Outcomes News

, Volume 820, Issue 1, pp 3–3 | Cite as

Adjuvant imatinib not cost effective in GIST at high recurrence risk

Clinical study
  • 3 Downloads

Reference

  1. Bussabawalai T, et al. Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand. Cost Effectiveness and Resource Allocation : 8 Jan 2019. Available from: URL: https://doi.org/10.1186/s12962-018-0169-9

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations